quantisnow
FeedTopReportsPricing
⌘K
Live feed
09:40:00·2d
NEWSRelease
Moderna Inc. logo

Moderna Receives European Commission Marketing Authorization for mCOMBRIAX, Moderna's mRNA Combination Vaccine Against Influenza and COVID-19

MRNA· Moderna Inc.
Health Care
Original source

Companies

  • MRNA
    Moderna Inc.
    Health Care

Recent analyst ratings

  • Jan 28UpdateBarclays$25.00
  • Jan 7UpdateUBS$34.00
  • Dec 12UpdateJefferies$30.00
  • Mar 13UpdateCitigroup$40.00
  • Feb 18UpdateBarclays$45.00
  • Jan 29UpdateGoldman$51.00

Related

  • NEWS2d
    Moderna Announces Initiation of Phase 3 Study of Investigational mRNA Pandemic Influenza Vaccine Candidate
  • NEWS2d
    Moderna Announces Data to be Presented at 2026 ASCO Annual Meeting
  • NEWS2d
    Moderna to Present at Upcoming Conferences in May 2026
  • NEWS6d
    Moderna to Present Phase 1/2 Data on Its Investigational Cancer Antigen Therapy mRNA-4359 as First-Line Therapy in Combination with Pembrolizumab in Locally Advanced or Metastatic Melanoma at the 2026 AACR Annual Meeting
  • NEWS8d
    Moderna to Report First Quarter 2026 Financial Results on Friday, May 1, 2026
  • NEWS17d
    Moderna to Present Revaccination Data for Its Investigational Seasonal Influenza Vaccine and for mRESVIA at ESCMID 2026
  • INSIDER17d
    SEC Form 4 filed by Mock James M
  • SEC27d
    Amendment: SEC Form SCHEDULE 13G/A filed by Moderna Inc.
quantisnow

Real-time market intelligence for retail investors. Press releases, filings, ratings, and insider flow - all in one stream.

All systems operational

Feeds

Press releasesAnalyst ratingsInsider tradingFDASECRSS feeds

Top lists

TrendingBy market capActive companiesAnalyst upgradesInsider purchasesFDA approvalsSEC filingsSectorsMarket reports

Company

AboutPricingPublish with usContact

Legal

Terms of usePrivacy policyCookie policy

© 2026 quantisnow.com · Democratizing insights since 2022